World Sight Day is an annual day of awareness held on the second Thursday of October, to focus global attention on blindness and vision impairment. World Sight Day 2016 takes place October 13. This year’s theme and call to action is “Stronger Together,” encouraging a focus on all stakeholders who are important for successful delivery of eyecare – Optos being one of those stakeholders.
Optos plc has the vision to be The Retina Company and is recognized as a leading provider of devices to eyecare professionals for improved patient care. Optos was founded and incorporated in 1992 by Douglas Anderson after his then five-year-old son went blind in one eye because a retinal detachment was detected too late. Although his son was having routine eye exams, the exams were uncomfortable, and difficult for a child to sit still through, which made it impossible for his eye doctor to conduct a complete exam and view the entire retina. Anderson’s mission was to commercialize a patient-friendly, easy to use and comfortable retinal imaging product that encompassed a digital widefield image of the retina in a single capture. Fast forward to 1999: the P200 received both 510k clearance from the FDA and the EU CE marking. Optos devices have been sold worldwide since …
In a world where the calendar is jammed with awareness months, should home eye safety and injury prevention really demand our attention? The answer is crystal clear. With two million eye injuries taking place each year in the United States1, eye safety is something in which everyone has a stake. Let’s look at the numbers:
— The U.S. Eye Injury Registry estimates that each year Americans suffer over two million eye injuries.
— The American Academy of Ophthalmology2 and the American Society of Ocular Trauma report that close to 45% of these injuries take place at home.
— Over 40% of eye injuries were caused by work related to home repairs, yard work, cleaning and cooking. Another 40% occurred during sports or recreation.
— Over one-third of injuries took place in the living areas in the home – places like the kitchen, bathroom, bedroom, and family room.
— There are 125,000 eye accidents a year involving household chemicals3. This totals over 10% of the total at-home eye injuries.
What’s even more sobering? It’s estimated that 90% of eye injuries can be prevented.
Building Public Awareness about Eye Injury at Home
In case studies, peer-reviewed papers, and a growing body of real-world practice, the ocular health community is improving patient management with the wider use of ultra-widefield (UWF™) imaging. Like all diagnostic breakthroughs, adoption of UWF imaging has been a long term process, paced by the accumulation of validated clinical experience. But now, more than a decade after UWF imaging was first introduced, the evidence is overwhelming that UWF imaging may have the potential to improve the diagnosis and management of a significant group of ocular diseases and conditions.
UWF imaging technology captures a 200-degree image of the retina – which enables ocular health practitioners to capture peripheral retinal images that can not be captured with conventional imaging methods. Starting with color (red and green) optomap imaging, Optos has systematically extended its UWF-based technology into a multi-modal platform that supports fundus autofluorescence (optomap af), fluorescein angiography (optomap fa) and indocyanine green angiography (optomap icg).
Where does UWF imaging have potential to improve diagnosis and treatment?
Proliferative Sickle Cell Retinopathy (PSR)
Recent research suggests that patients suffering from various systemic disorders may have their disease state impacted by the addition of ultra-widefield (UWF™) retinal imaging to their examination. New research has found that patients with sickle cell disease may benefit from UWF retinal imaging for the diagnosis and management of sickle cell retinopathy (SCR).
Sickle cell disease is an inherited disorder in which the body produces blood cells with abnormally formed hemoglobin. Symptoms include anemia, severe and chronic pain, infection, hypertension, hand and foot swelling, leg ulcers, and retinal vascular changes1. Sickle cell disease can also have an impact on vision. Sickle cell retinopathy mainly affects the peripheral retinal vasculature2 as the result of abnormal, sickle-shaped blood cells becoming trapped in the small blood vessels of the eye3. Non-proliferative SCR, characterized by retinal hemorrhage from superficial blood vessels, can cause loss of visual acuity. Proliferative SCR is marked by vascular occlusions that lead to localized ischemia, neovascularization, and in later stages blindness from vitreous hemorrhage or tractional retinal detachment. Patients with sickle cell disease are at varying degrees of risk of developing SCR, but those with the type SC or S-Thal hemoglobin genotypes are at significant risk for developing …
Over the past decade Optos has expanded the capability of its core ultra-widefield fundus imaging technology, and with that has come a widening number of clinical applications.
Ultra-widefield (UWF™) imaging technology – enabling the capture of a 200-degree view of the retina without dilation – gives ocular health practitioners imagery and diagnostic information that can’t be provided by conventional imaging methods. Starting with color (red and green) optomap imaging, Optos has systematically extended its UWF-based technology into a multi-modal platform that supports fundus autofluorescence (optomap af), fluorescein angiography (optomap fa) and indocyanine green angiography (optomap icg).
Optos has also been incorporating the latest developments in image processing, providing users with important diagnostic and treatment management tools. In its latest software release, Optos has incorporated an advanced, proven stereographic projection algorithm that corrects for peripheral image variations that occur when a spherical image is flattened.
While the most common use of UWF technology may be in the diagnosis and treatment of diabetic retinopathy (DR), optomap imaging is also being used for characterizing pediatric retinal disease; age-related macular degeneration (AMD); retinal breaks and tears; uveitis, ocular oncology; central serous chorioretinopathy (CSCR); retinal vein occlusion (RVO); and a growing list of other …